Symbol Lookup

Wednesday April 16, 2014 9:45 AM ET. Data delayed 15 minutes.
0.47
0.00 (1.05%)
Bid/Lots
0.46/55
Ask/Lots
0.47/25
Open/Prev Close
0.46/0.47
Day Range
0.46-0.47
52-Week Range
0.40-0.98
Vol/Avg Daily Vol
1.1K/46.7K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

0 New Today
Guided Therapeutics Receives May 8th Meeting Date from FDA to Discuss LuViva(R) Advanced Cervical Scan PMA Application
8:59AM ET on Thursday Apr 10, 2014 by Business Wire

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has been given a face-to-face meeting date of May 8, 2014, by the U.S. Food and Drug Administration (FDA), to discuss the company's resp...

Guided Therapeutics' LuViva(R) Honored as Finalist in the Medical Device Excellence Awards
8:59AM ET on Wednesday Apr 09, 2014 by Business Wire

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP), today announced that the LuViva(R) Advanced Cervical Scan, its non-invasive device used to detect cervical disease instantly at the point of care, has been selected as ...

Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva(R) Advanced Cervical Scan
8:05AM ET on Thursday Mar 27, 2014 by Business Wire

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration (FDA) in the next 60 to 90 days. Thi...

Guided Therapeutics Reports Fourth Quarter and 2013 Results
4:44PM ET on Wednesday Mar 26, 2014 by Business Wire

--LuViva(R) Advanced Cervical Scan momentum building with key opinion leaders; increasing number of product evaluations

--Large scale screening trials initiated in Turkey and Nigeria, with additional screening evaluations planned for Ken...

HPV Screening Beneficial for Guided Therapeutics' LuViva(R) Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries
8:05AM ET on Tuesday Mar 18, 2014 by Business Wire

The March 12, 2014, recommendation by a U.S. Food and Drug Administration (FDA) panel to use human papillomavirus (HPV) testing as an alternative to Pap testing for screening of women for cervical cancer has the potential t...

Company Information

Guided Therapeutics, Inc. is a medical technology company focused on developing medical devices. The Company's primary focus is the development of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, especially esophageal. Its technology, including products in research and development, primarily relate to biophotonics technology for the non-invasive detection of cancers. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix.

CONTACT INFORMATION

HeadquartersSuite D, 5835 Peachtree Corners East
NORCROSS, GA, United States 30092
Phone770-242-8723
Fax770-242-8639

EXECUTIVE OFFICERS

Chairman of the BoardMichael James
Chief Executive OfficerGene Cartwright
Independent Vice Chairman of the BoardRonald Hart
Senior Vice President - EngineeringRichard Fowler
Independent DirectorJohn Imhoff

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$33.6MBeta0.66
Revenue (TTM)$1.8MEPS$-0.11
Shares Out.71.7MBook Value$0.02
Guided Therapeutics Inc does not pay a dividend.P/E--
Price/Sales (TTM)18.7
P/Cash Flow (TTM)--
Operating Margin-358.43%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample